![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Bemnifosbuvir and ruzasvir are potent HCV DAAs with favorable
antiviral profiles against major HCV NS5A and NS5B RAVs supporting use in combination
|
|
|
AASLD 2023 nov 10-14
https://www.aasld.org/the-liver-meeting
Qi Huang, Steven S. Good, Dawei Cai, Nancy G.B. Agrawal, Jean-Pierre Sommadossi
Atea Pharmaceuticals, Boston, MA, US
![1113231](../images/111323/111323-10/1113231.gif)
![1113232](../images/111323/111323-10/1113232.gif)
![1113233](../images/111323/111323-10/1113233.gif)
![1113234](../images/111323/111323-10/1113234.gif)
![1113235](../images/111323/111323-10/1113235.gif)
![1113236](../images/111323/111323-10/1113236.gif)
![1113237](../images/111323/111323-10/1113237.gif)
![1113238](../images/111323/111323-10/1113238.gif)
![1113239](../images/111323/111323-10/1113239.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|